Anavex Life Sciences to Present at Noble Capital Markets’ Thirteenth Annual Investor Conference

NEW YORK – January 23, 2017 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced that Christopher U. Missling, PhD, President…

Money 1 1120 x 480

Anavex Life Sciences Receives Grant From Rettsyndrome.org to Commence U.S. Phase 2 Trial in 2017

ANAVEX 2-73 has U.S. FDA Orphan Drug Designation for Rett Syndrome NEW YORK and Cincinnati, Ohio – January 19, 2017 – Anavex Life Sciences Corp. (Nasdaq: AVXL) and the International Rett Syndrome Foundation, doing business as Rettsyndrome.org today announced that Rettsyndrome.org has committed a financial grant of a minimum of $0.6 million to cover the…

Anavex Life Sciences Obtains Permanent Dismissal of All Claims in Securities Lawsuit

NEW YORK – January 3, 2017 – Anavex Life Sciences Corp. (Nasdaq: AVXL) a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, announces the dismissal with prejudice in its entirety of the Cortina v.…

Anavex Life Sciences Reports Fiscal 2016 Financial Results

Conference Call and Webcast Today at 4:30 p.m. ET to Discuss Financial Results and Clinical Progress NEW YORK – December 12, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system…

Anavex Life Sciences Announces 12-Month Data of ANAVEX 2-73 in a Phase 2a Study in Mild-to-Moderate Alzheimer’s Disease Patients

Data presentation at CTAD 2016 NEW YORK, NY – December 8, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL) today announced a positive 57-week update from its Phase 2a study in mild-to-moderate Alzheimer’s disease (AD) patients for ANAVEX 2-73, which targets cellular homeostasis. The study met both primary and secondary endpoints.…

Anavex Life Sciences to Present at Annual Mental Health Parity Addiction Equity Act Roundtable at U.S. Capitol, Washington, DC

NEW YORK – December 1, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL) today announced that Christopher U. Missling, Ph.D., President and Chief Executive Officer, will participate on a panel comprising 14 representatives from government and industry at the Fourth Annual Mental Health Parity and Addiction Equity Act (MHPAEA) Business Roundtable.…

Anavex Life Sciences Appoints Three Distinguished Researchers To Scientific Advisory Board

NEW YORK, NY – November 28, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced the appointment of three distinguished…

Anavex Life Sciences Announces Data on 41-Week Treatment of ANAVEX 2-73 for Patients with Alzheimer’s Disease

Investigational Treatment suggests to curb Cognitive and Functional Decline − Full data to be presented at CTAD 2016 − NEW YORK, NY – November 22, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL) today announced a positive 41-week update from its Phase 2a study in mild-to-moderate Alzheimer’s disease (AD) patients for…

Anavex Life Sciences Novel Sigma-1 / Sigma-2 Ligand Shows Encouraging Results as an Analgesic in Animal Models of Neuropathic and Visceral Pain

Preclinical Data for ANAVEX 1066 Presented at Society for Neuroscience Annual Meeting NEW YORK, NY – November 14, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL) today reported encouraging preclinical efficacy for the treatment of neuropathic pain and visceral pain with their novel compound, ANAVEX 1066. The poster titled “Mixed sigma-1…

Anavex Life Sciences and Ariana Pharma Collaborate to Accelerate Timelines and Improve Efficiency of Alzheimer’s and Parkinson’s Clinical Development Programs

NEW YORK, NY – October 5, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced a collaboration with Ariana Pharma…